Fortitude Family Office’s Pulse Biosciences PLSE Stock Holding History

Fortitude Family Office’s Portfolio PLSE Stock Details PLSE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$864	Buy	+40	New	+$738	﹤0.01%	1549

Other funds holding PLSE

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

PCM

Portolan Capital Management Boston, Massachusetts $1.88B AUM 115.74% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

GAM

Griffin Asset Management New York $887M AUM 21.42% 1-Year Est. Return

LMR Partners London, United Kingdom $45.4B AUM 60.68% 1-Year Est. Return

Fortitude Family Office's PLSE Position: Q1 2026 in Review

Fortitude Family Office opened a new position in Pulse Biosciences (PLSE) in Q1 2026: 40 shares worth $864. The stake represents ﹤0.01% of the portfolio and ranks #1549 among its holdings.

96 funds tracked by Wall St. Rank hold PLSE as of Q1 2026.

Fortitude Family Office held 40 shares of Pulse Biosciences worth $864 as of Q1 2026.
Pulse Biosciences was a new Fortitude Family Office position in Q1 2026.
Pulse Biosciences made up ﹤0.01% of Fortitude Family Office's portfolio in Q1 2026, its #1549 holding.
96 funds tracked by Wall St. Rank held Pulse Biosciences as of Q1 2026.

Based on Fortitude Family Office's 13F filing for Q1 2026, filed 16 Apr 2026.